NPI: 1417076829 · LEESBURG, VA 20176 · Professional Counselor · NPI assigned 03/28/2007
Authorized official PINCINCE, DEBORAH controls 20+ related entities in our dataset. Read more
| Authorized Official | PINCINCE, DEBORAH (ADMINISTRATOR) |
| NPI Enumeration Date | 03/28/2007 |
Other providers sharing the same authorized official: PINCINCE, DEBORAH
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 8,707 | $305K |
| 2019 | 17,045 | $523K |
| 2020 | 55,166 | $899K |
| 2021 | 172,788 | $2.80M |
| 2022 | 132,793 | $1.97M |
| 2023 | 93,482 | $1.32M |
| 2024 | 79,636 | $1.21M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 174,615 | 153,502 | $2.13M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 56,489 | 48,806 | $1.40M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21,119 | 18,976 | $1.11M |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 14,477 | 13,643 | $916K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10,667 | 9,517 | $705K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 8,489 | 7,848 | $358K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 17,677 | 15,804 | $196K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6,325 | 5,933 | $189K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6,336 | 5,656 | $184K |
| 99401 | 5,533 | 5,247 | $123K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,704 | 1,592 | $107K |
| 90715 | 3,248 | 3,042 | $102K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 8,042 | 3,707 | $91K |
| 86580 | 12,428 | 11,475 | $88K | |
| 90674 | 4,737 | 4,386 | $79K | |
| 3074F | 25,507 | 23,237 | $77K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 689 | 644 | $67K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 1,059 | 994 | $65K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,658 | 1,421 | $65K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 17,117 | 15,653 | $62K |
| 3078F | 20,821 | 19,052 | $61K | |
| 90750 | 527 | 484 | $60K | |
| 90739 | 392 | 365 | $54K | |
| 1160F | 24,981 | 22,514 | $51K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4,327 | 3,885 | $47K |
| 1159F | 22,449 | 20,439 | $47K | |
| 90686 | 3,148 | 2,912 | $41K | |
| 91322 | 339 | 322 | $40K | |
| 90746 | 798 | 733 | $38K | |
| 1036F | 29,757 | 26,541 | $37K | |
| 91320 | 336 | 321 | $36K | |
| 90716 | 369 | 329 | $35K | |
| 3008F | 23,104 | 20,989 | $35K | |
| 90651 | 188 | 173 | $30K | |
| 90734 | 431 | 422 | $27K | |
| 3079F | 8,150 | 7,615 | $27K | |
| 90619 | 306 | 299 | $26K | |
| 90682 | 631 | 567 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,092 | 1,745 | $19K |
| 90707 | 305 | 262 | $16K | |
| 0064A | 488 | 440 | $13K | |
| 90661 | 398 | 389 | $11K | |
| 3075F | 3,318 | 3,141 | $11K | |
| 99201 | 362 | 317 | $9K | |
| 0081A | 302 | 259 | $8K | |
| 90480 | 780 | 744 | $7K | |
| 81002 | 3,146 | 2,851 | $7K | |
| 0004A | 277 | 244 | $7K | |
| 0082A | 218 | 202 | $6K | |
| 0134A | 201 | 177 | $6K | |
| 0071A | 167 | 155 | $6K | |
| 90713 | 165 | 163 | $5K | |
| 90656 | 256 | 252 | $5K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2,519 | 1,910 | $5K |
| 3077F | 1,433 | 1,326 | $5K | |
| 0001A | 170 | 154 | $5K | |
| 3080F | 1,091 | 1,024 | $4K | |
| 0072A | 113 | 107 | $4K | |
| 81025 | 563 | 534 | $3K | |
| 99402 | 151 | 145 | $3K | |
| 0124A | 104 | 93 | $3K | |
| 90662 | 319 | 299 | $3K | |
| 0011A | 109 | 97 | $3K | |
| 0083A | 103 | 87 | $3K | |
| 0002A | 95 | 89 | $3K | |
| 90673 | 32 | 32 | $2K | |
| 0031A | 53 | 50 | $1K | |
| 36415 | Collection of venous blood by venipuncture | 518 | 477 | $1K |
| 0074A | 30 | 24 | $778.99 | |
| 90632 | 17 | 13 | $718.54 | |
| 80061 | Lipid panel | 35 | 34 | $430.27 |
| 0012A | 14 | 12 | $400.47 | |
| 86328 | 34 | 33 | $310.76 | |
| G0008 | Administration of influenza virus vaccine | 146 | 142 | $98.42 |
| 82947 | 41 | 36 | $94.48 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 12 | 12 | $11.92 |
| 91308 | 163 | 113 | $0.00 | |
| 4040F | 14 | 13 | $0.00 | |
| 4120F | 57 | 57 | $0.00 | |
| 91300 | 32 | 26 | $0.00 | |
| 91313 | 17 | 15 | $0.00 | |
| 4124F | 145 | 145 | $0.00 | |
| 1000F | 42 | 41 | $0.00 |